Halozyme Therapeutics has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio and its subcutaneous injection platform. The ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果